Filing Analysis
Xtant Medical Holdings entered into an exclusive U.S. distribution agreement with Dilon Technologies for the FDA-approved HEMOBLAST® Bellows surgical hemostatic agent. The deal includes a $5.0 million upfront exclusivity fee and the hiring of approximately 20 Dilon sales personnel by Xtant.
Key Facts
- Agreement signed on April 10, 2026, granting Xtant exclusive rights to import, market, and sell HEMOBLAST® Bellows in the U.S.
- Xtant paid a $5.0 million exclusivity fee, which is subject to repayment under specific termination circumstances.
- Xtant hired approximately 20 sales personnel from Dilon to support the product's distribution.
- Dilon will continue to manufacture the product in France and supply it to Xtant at a specified transfer price.
- The agreement includes the transition of Dilon's existing U.S. customer base and assignment of existing customer contracts to Xtant.
- There are no minimum purchase requirements for Xtant under the terms of the agreement.
Xtant Medical Holdings, Inc. announced its financial results for the fourth quarter and full year ended December 31, 2025. The filing focuses on the presentation of non-GAAP adjusted EBITDA, which excludes impacts from recent divestitures and acquisitions.
Key Facts
- Financial results reported for the three months and year ended December 31, 2025.
- The company utilized non-GAAP adjusted EBITDA to exclude non-cash compensation and divestiture/acquisition-related expenses.
- Specific divestitures mentioned include the non-core Coflex/CoFix assets and the international hardware business.
- Adjustments were also made for acquisition-related fair value adjustments and separation-related expenses.
Xtant Medical received a $10.7 million payment from Companion Spine, concluding the financial settlement of its previously announced divestiture of Paradigm Spine and certain hardware assets. The final aggregate purchase price reached $21.4 million, and the company used $2.8 million of the proceeds to reduce its term loan debt.
Key Facts
- Received $10.7 million on February 27, 2026, covering an $8.2 million note plus interest and adjustments.
- Total divestiture proceeds increased to $21.4 million from an initial $19.2 million estimate.
- Used $2.8 million of the received funds to prepay a portion of the MidCap Financial Trust term loan.
- Remaining term loan principal balance stands at $11.1 million as of the report date.